Drinidene is the analgesic agent.

Prinomide is a carbamoylpyrrolepropionitrile derivative patented by Ciba-Geigy A.-G. as a nonsteroidal anti-inflammatory drug that has disease-modifying activity in rheumatoid arthritis. In clinical trials, Prinomide demonstrate significant improvement in symptom score and laboratory variables.

Benzpiperylone was studied as a synthetic anti-inflammatory drug. Information about the nowadays use of this compound is not available.

There is no information about biological and/or pharmacological application of phenbutazone sodium glycerate.

Fenamole is a muscle relaxant. It is effectively inhibits muscle spasms at good levels for a four hours and at significant levels for six hours. Clinical benefits were derived in patients with spasticity-spasm for periods up to 24 hours after a single oral dose. Fenamole is relatively free of adverse side effects particularly in the central nervous system. It is a potent copper chelator. It was once investigated as a potential antirheumatic agent in man.

Cloticasone propionate is an ester of an antiinflammation steroid cloticasone.

Triflumidate is a fluoroalkanesulfonanilide. It had been identified for clinical trials. This non-steroidal compound is an anti-inflammatory agent.

Dexoxadrol is a sigma receptor agonist. Dexoxadrol, the D-isomer of dioxodrol, which produces PCP-like behavioural effects and displaces bound [3H]PCP, was a potent blocker of the PCP-sensitive, voltage-gated K+ channel. Dexoxadrol was developed as analgesics for use in humans, however, severe side effects including psychotomimetic effects, unpleasant dreams and aberrations stopped the clinical evaluation of dexoxadrol. Dexoxadrol is a NMDA receptor antagonist, which possesses high affinity to the phencyclidine binding site within the NMDA receptor associated ion channel.

Pirazolac is a pyrazole-acetic acid derived from indomethacin. It is a nonsteroidal anti-inflammatory agent. Pirazolac concentration-relatedly inhibited the accumulation of prostanoids in incubates of human gastric mucosa, but this inhibition was less than that by indomethacin and other commonly used non-steroidal anti-inflammatory drugs. Pirazolac was at least as effective as sulindac in the treatment of patients with rheumatoid arthritis. The abnormal activity of neutrophils from patients with rheumatoid arthritis was partially corrected with pirazolac. Patients with ankylosing spondylitis benefited similarly from treatment with pirazolac and indomethacin. Pirazolac was developed in an effort to overcome the adverse gastrointestinal effects of indomethacin. However, more patients with ankylosing spondylitis withdrew from treatment because of intolerable adverse events with pirazolac than with indomethacin in a clinical trial. In patients with rheumatoid arthritis, pirazolac had similar tolerability to sulindac.

Butacetin is an anilide derivative with potent analgesic and antipyretic activity. Butacetin shows marked analgesic and anti-inflammatory potencies in the mouse abdominal constriction assay and the carrageenan-induced rat paw edema. Butacetin has the advantage of demonstrating much lower gastro-toxicity than currently available NSAIDs.